You are here: Industry Insights > AstraZeneca

News List

AstraZeneca's Imfinzi survival win shores up the one lung cancer advantage it has fiercepharma
May 29, 2018
AstraZeneca’s Imfinzi already has an FDA approval in the lung cancer maintenance setting under its belt, something none of its rivals will be able to say for a while. And Friday, it hit another key benchmark to stretch out that lead.
Luye Pharma acquires AstraZeneca's signature products biospectrumasia
May 29, 2018
A Move Aimed at Enriching the Existing CNS Portfolio and Enhancing Strategic Synergy across International Markets
AstraZeneca opens South San Francisco facility housing 400 R&D staff fiercebiotech
May 29, 2018
AstraZeneca has officially opened its new research facility in South San Francisco, bundling five of its Bay Area sites into a single unit at the heart of California’s biotech cluster.
USFDA approves AstraZeneca's Lokelma biospectrumasia
May 22, 2018
Lokelma is approved for the treatment of adults with hyperkalaemia
AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets worldpharmanews
May 11, 2018
AstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK...
AstraZeneca sells rights for Seroquel to China's Luye Pharma biospectrumasia
May 10, 2018
In FY 2017, Seroquel generated annual sales of $85mn
t's another dust-up over AstraZeneca's CEO pay, this time focused on his bonus fiercepharma
May 09, 2018
AstraZeneca slashed CEO Pascal Soriot’s total compensation by 34% to £9.4 million ($12.7 million) in 2017, but that pay cut wasn’t deep enough for one influential voice on corporate governance...
AstraZeneca continues yard-sale strategy with $538M Seroquel rights deal fiercepharma
May 09, 2018
AstraZeneca is back at it again with asset sales. The company, which has taken some flak for a series of deals to offload asset rights, inked an agreement with Luye Pharma for legacy antipsychotic Seroquel and an extended-release version...
AZ’s immunotherapy combo fails again in lung cancer pharmaphorum
April 26, 2018
AstraZeneca had placed its immunotherapy Imfinzi (durvalumab) at the centre of its efforts to rebuild its sales – but after a shock failure last year in first line lung cancer, the drug has also come up short in previously treated patients.
Combination of AstraZeneca's Imfinzi, tremelimumab fails to hit goals of third-line lung cancer study firstwordpharma
April 25, 2018
AstraZeneca said that the phase III ARCTIC study of the combination of Imfinzi (durvalumab) and tremelimumab failed to meet the significant and clinically significant improvement in its primary endpoint

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page